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The combination of reduced-intensity conditioning, 188rhenium anti-CD66 radioimmunotherapy, and in vivo
T cell depletion was successfully applied in elderly patients with acute myeloid leukemia or myelodysplastic
syndrome. Within a prospective phase II protocol, we investigated whether a dose reduction of alemtuzumab
(from 75 mg to 50 mg MabCampath) would improve leukemia-free survival by reducing the incidence of
relapse. Fifty-eight patients (median age, 67 years; range, 54 to 76) received radioimmunotherapy followed
by ﬂudarabine 150 mg/m2 and busulfan 8 mg/kg combined with either 75 mg (n ¼ 26) or 50 mg (n ¼ 32)
alemtuzumab. Although we observed a trend towards a shorter duration of neutropenia in the 50 mg group
(median, 19 versus 21 days; P ¼ .07), the time from transplantation to neutrophil and platelet engraftment as
well as the overall incidence of engraftment did not differ. The incidence of severe acute graft-versus-host
disease tended to be higher after the lower alemtuzumab dose (17% versus 4%; P ¼ .15). No signiﬁcant dif-
ferences in the cumulative incidences of relapse (38% versus 35%; P ¼ .81) or nonrelapse mortality (46% versus
27%; P ¼ .31) were observed. Accordingly, disease-free and overall survival were not signiﬁcantly different
between groups. Although the feasibility of radioimmunotherapy plus reduced-intensity conditioning could
be demonstrated in elderly patients, the dose reduction of alemtuzumab had no positive impact on overall
outcome.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION of leukemia patients are over 65 years old and, therefore,
Allogeneic hematopoietic stem cell transplantation (SCT)
is a potentially curative treatment for adults suffering from
acute myeloid leukemia (AML) or myelodysplastic syndrome
[1-3]. This applies especially for patients with high-risk dis-
ease, as deﬁned by cytogenetic or molecular markers [4-7],
where allogeneic SCT represents the consolidation therapy
with the highest antileukemic efﬁcacy [8,9].
The gain of graft-versus-leukemia effects is offset by
considerable treatment-related mortality of up to 30%,
especially in elderly and unﬁt patients [4,10]. More than 55%edgments on page 1759.
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ty for Blood and Marrow Transplantation.suffer from age-related comorbidities. In addition, elderly
patients with AML more frequently have high-risk disease
with complex aberrant cytogenetics [11,12]. Furthermore,
allogeneic SCT in older people comes with special problems,
such as an increased incidence and lower tolerability of
severe acute graft-versus-host disease (GVHD) and the
aforementioned comorbidities and resultant complications
[13,14].
Thus, several groups around the world have tried to
develop reduced-intensity preparative regimens (RIC),
especially tailored for older patients [15]. Because of the
lower antiproliferative activity of RIC, the incidence of
relapse has been shown to be higher with this procedure
[16], which is why investigators tried to add speciﬁc antitu-
moral strategies that add antileukemic efﬁcacy but are not
associated with excess extramedullary toxicity. Therefore,
radioimmunotherapy (RIT) has been tested in the context of
Table 1
Patient Characteristics
Characteristic 50 mg Cam 75 mg Cam P Value
Clinical parameters
No. of patients 32 26
Age, median (range), yr 69 (61-74) 65 (54-76) .00
Male/female 17/15 (53%/47%) 12/14 (46%/54%) .79
Disease
De novo AML 16 (50%) 15 (58%) .97
sAML 2 (6%) 1 (4%)
AML out of MDS 9 (28%) 7 (27%)
MDS 5 (16%) 3 (12%)
Status before SCT
CR 22 (69%) 21 (81%) .57
Chemo sensitive with
residual blasts
4 (13%) 1 (4%)
Refractory 5 (16%) 2 (8%)
Relapse d 1 (4%)
Untreated 1 (3%) 1 (4%)
Cytogenetic risk
Intermediate 20 (63%) 16 (62%) 1.00
High 12 (38%) 10 (38%)
FLT3/NPM1
Mutated/mutated 3 (9%) 1 (4%) .77
Mutated/wild type 1 (3%) 1 (4%)
Wild type/mutated 3 (9%) 2 (8%)
Wild type/wild type 18 (56%) 6 (23%)
Unknown 7 (22%) 16 (62%)
Donor
10/10 Matched sibling 5 (16%) 7 (27%) .59
10/10 MUD 19 (59%) 14 (54%)
9/10 MUD 8 (25%) 5 (19%)
Gender matched 14 (44%) 18 (69%) .07
Gender mismatched 18 (56%) 8 (31%)
Graft source
PBSC 30 (94%) 26 (100%) .50
Bone marrow 2 (6%) d
CMV .53
Recipient
pos./donor pos.
10 (31%) 5 (19%)
Recipient
pos./donor neg.
13 (41%) 12 (46%)
Recipient
neg./donor pos.
3 (9%) 1 (4%)
Recipient
neg./donor neg.
6 (19%) 8 (31%)
Sorror score
Median (range) 1 (0-7) 1 (0-7) .73
Cam indicates Campath-1H; sAML, secondary AML; MDS, myelodysplastic
syndrome; CR, complete remission; FLT3, Fms-like tyrosine kinase-3; NPM1,
nucleophosmin; MUD, matched unrelated donor; PBSC, peripheral blood
stem cells; pos, positive; neg, negative.
Data presented are n (%), unless otherwise indicated.
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primary and secondary hematopoietic organs (bone marrow,
spleen). Both direct (eg, anti-CD45, anti-CD33) and indirect
(eg, anti-CD66) targeting strategies have been applied in the
context of allogeneic SCT. The use of 188rhenium (Re)-labeled
anti-CD66 monoclonal antibodies (mAb) requires a residual
proportion of differentiated hematopoietic cells to eliminate
leukemic cells via the so called cross-ﬁre effect of the
ß-emitter. The clinical feasibility of this conditioning
regimen has been proven by several investigators, including
ourselves [17-19].
The ﬁrst results of a phase II trial at our institution by
Lauter et al. [19] showed that patients receiving RIC plus RIT
and in vivo T cell depletion with alemtuzumab (Campath-
1H; Genzyme, Cambridge, MA, USA) had a similar survival
and incidence of relapse when compared with that of
younger historic cohort receiving the same chemothera-
peutic backbone of ﬂudarabine and busulfan only. Never-
theless, extramedullary toxicity had been lower, as was the
incidence and severity of acute GVHD [19].
As the incidence of relapse had not been decreased by the
addition of RIT in this interim analysis, we speculated
whether a dose reduction of alemtuzumab would foster
graft-versus-leukemia effects by less stringent T cell deple-
tion without substantially increasing the risk of acute and
chronic GVHD.
METHODS
Study Design and Patients
Fifty-eight patients at a median age of 67 (range, 54 to 76) received SCT
with RIT as part of conditioning therapy between October 2003 and October
2012. Included patients had to be 55 years of age, suffering from refractory
cytopenia with multilineage dysplasia, excessive blasts type 1 and 2, or have
AML with < 20% blasts after induction therapy. Furthermore, they needed
appropriate health collated by the Sorror score and the availability of a
donor with  90% HLA alleles (HLA-A, B, C, DRB1, DQB1 on the 4-digit level)
matched [20]. After recruitment of 26 patients, the trial was amended to be
continued with a reduced dose of Campath-1H. This prospective phase II
trial and the subsequent amendment were approved by the local ethics
committee and were performed in consensus with the Helsinki declaration.
All patients gave written informed consent before participation. Overall,
61 patients were recruited. Three patients were excluded because of pro-
tocol violations and conﬂicts with inclusion criteria. For the ﬁnal analysis,
58 patients having received either 50 mg (n ¼ 32) or 75 mg alemtuzumab
(n ¼ 26) were available. Patients’ characteristics are summarized in Table 1.
Preparative Regimen
Radioimmunotherapy
Scintimun-Granulocyte (Schering AG, Switzerland) contains a
radioisotope-labeled anti-CD66 mAb that targets promyelocytes and pro-
genitor cells of the myeloid lineage and is generally used for bone marrow
scintigraphy. If coupled to the ß-emitter 188Re, a cross-ﬁre irradiation of
leukemia blasts in the bone marrow environment up to myeloablative doses
can be achieved. This is useful for intensifying the conditioning regimen
combined with reduced extramedullary toxicity before SCT [17,21,22].
A median dose equivalent of 12.1 GBq 188Re (range, 6.6 to 17.7) was
administered at day 11 or 9.
Alemtuzumab
MabCampath (Genzyme) is a humanized anti-CD52 monoclonal anti-
body. Surface glycoprotein CD52 is expressed on mature T and B lympho-
cytes leading to an effective GVHD prophylaxis [23,24]. Campath-1H was
administered i.v. either 10 mg on day 5, 20 mg on day 4, and 3 (total,
50 mg) or 5mg at day8,10mg day7, and 20mg from day6 to4 (total,
75 mg).
RIC
We started RIC for all study patients with ﬂudarabine i.v. (30 mg/m2)
from day 8 or 7 until 4 or 3 before SCT (total 150 mg/m2). Busulfan
was administered orally on days 3 and 2 (cumulative dose 8 mg/kg).
Cyclosporine A per os was given daily beginning at day 1 with a target
trough blood level of 150 to 250 ng/mL. The regimen and the modiﬁcations
implemented after the ﬁrst 26 patients are illustrated in Figure 1.Chimerism analyses
Chimerism tests were performed twice weekly, according to local
standards, in all 58 patients. Starting at day þ 7 after transplantation, DNA
was obtained from unfractionated peripheral white blood cells and used for
chimerism testing [25].
Supportive care
Antifungal prophylaxis was performed with 2200 mg ﬂuconazole/day
and acyclovir 3200 mg/day starting day7. Trimethoprim-sulfamethoxazole
was administered twice each week before starting RIC and after hematologic
engraftment. Cytomegalovirus (CMV) plasma DNA was monitored twice
weekly and preemptive therapy with ganciclovir was started in case of
positivity.
Statistics
The primary endpoint of this trial was the incidence of relapse within
12 month after SCT. Remission and relapse criteria were applied as pub-
lished by Cheson et al. [26] and GVHD according to Przepiorka and Sullivan
[27,28]. Secondary endpoints were nonrelapse mortality (NRM), and overall
and disease-free survival (OS, DFS). Besides descriptive statistics (median,
range) we used t-test and Fisher’s exact test for explorative analyses.
P values of 2-sided tests are regarded as signiﬁcant if < .05. Statistics were
Figure 1. Comparison in treatment protocol and amendments between study and control group. Re indicates radioimmunotherapy; Cam, Campath-1H; Flu,
ﬂudarabin; Bu, busulfan; CsA, cyclosporine A.
Table 2
Summary of Results
Characteristic 50 mg Cam 75 mg Cam P Value
Clinical parameters
Time in hospital, 19 (14-49) 21 (11-73) .48
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Kaplan and Meier (1958) in an intention to treat analysis and compared by
log-rank test. The cumulative incidence of relapse/severe acute GVHD as
well as relapse/NRM were determined as competing events [29]. Age,
remission status at transplantation, dose of Campath-1H, and CMV seros-
tatus of the recipient and donor type (sibling versus unrelated) were
selected as potential confounding factors and included in multivariate Cox
regression analyses. Data cut off was October 31, 2013.median (range), d
In-hospital mortality, n 1 (3%) 1 (4%) 1.00
Transfused CD34þ cells,
median (range), 
106/kg
6 (1.2-10.3) 6.7 (2.9-13.5) .14
Engraftment
Neutrophils > .5  109/L,
median (range), d
17 (11-26) 17 (10-47) .39
Duration of neutropenia,
median (range), d
19 (9-32) 21 (14-49) .07
Platelets > 50  109/L,
median (range), d
13 (7-38) 13 (9-19) .13
Chimerism > 95%,
median (range), d
11 (10-19) 14 (9-28) .07
Donor lymphocyte
infusion
4 (13%) 8 (31%) .11
Transfusion
RCC, median (range) 6 (0-22) 5 (0-32) .75
PC, median (range) 4 (1-21) 4 (2-20) .75
Acute GVHD
Grade I to IV 18 (55%) 14 (54%) .87
Severe (III and IV) 5 (17%) 1 (4%) .15
Chronic GVHD
None 18 (56%) 16 (62%) .86
Extensive 11 (34%) 7 (27%) .58RESULTS
Engraftment
The median time to reach more than .5  109/L neutro-
phils after SCT in patients receiving 50 mg Campath-1H was
17 days (range, 11 to 26). The duration of neutropenia after
the start of RIT was 19 days (range, 9 to 32), which tended to
be shorter compared with that of those who received 75 mg
Campath-1H group (median, 21; range, 14 to 49; P ¼ .07).
Platelets surpassed 50  109/L 3 days in a row without
transfusion after a median of 13 days after SCT (range, 7 to
38). One patient (3%) did not achieve platelet engraftment
during the in-hospital stay whereas 4 patients (15%; P ¼ .16)
in the 75 mg Campath-1H group did not reach this limit.
Donor chimerism > 95% was detected after a median of
11 days (range, 10 to 19) versus 14 days (range, 9 to 28) in the
50 mg versus the 75 mg Campath-1H cohort, respectively
(P ¼ .07). All patients of the 50 mg Campath-1H group ﬁnally
engrafted, whereas 1 patient of the 75 mg Campath-1H
group did not reach a chimerism > 95% during follow-up.Limited 3 (9%) 3 (12%)
Causes of death
Relapse 12 (44%) 10 (52%) .72
Infection/sepsis 8 (30%) 6 (32%)
GVHD 2 (7%) 1 (5%)
Microangiopathic
hemolytic anemia
1 (4%) 0
Bleeding 2 (7%) 0
Others (eg, suicide,
mesenteric ischemia,
sec. malignancy)
2 (7%) 2 (11%)
Infectious complications
CMV DNA PCR 23 (100%) 16 (94%) .57
Aspergillus-antigen
index > 1.0
8 (25%) 6 (23%) .85
RCC indicates red cell concentrates; PC, Platelet concentrate; sec, secondary.
Data presented are n (%), unless otherwise indicated.Patient and Treatment Characteristics
Patient and transplantation characteristics are summa-
rized in Table 2. The median follow-up of surviving patients
was 1264 days (range, 358 to 1621).
Patients in the 50 mg group were signiﬁcantly older than
those in the 75 mg Campath-1H patients (69 years; range,
61 to 74 versus 65 years; range, 54 to 76; P¼ .001). A median
of 6  106 CD34þ stem cells per kg recipient body weight
(range, 1.2 to 10.3  106) were transfused to the 50 mg
Campath-1H group. The median hospital stay for the
transplantation procedure was 19 days (range, 14 to 49
days). One patient died before discharge. Six (range, 0 to 22)
packed red cell concentrates and 4 (range, 1 to 21) platelet
Table 3
Overall Survival, Disease-Free Survival, Relapse, and NRM 100 Days, One
Year, and Two Years after SCT
Outcome 50 mg Cam 75 mg Cam P Value
OS .38
Day 100 81% 85%
1 Year 50% 46%
2 Year 22% 38%
DFS .38
Day 100 78% 81%
1 Year 40% 42%
2 Year 16% 38%
Relapse .81
Day 100 6% 12%
1 Year 28% 35%
2 Year 38% 35%
NRM .31
Day 100 16% 8%
1 Year 32% 23%
2 Years 46% 27%
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difference in transfusion requirements according to
Campath-1H dose.
Relapse and NRM
As illustrated in Figure 2 and listed in Table 3, the
cumulative incidence of relapse in the 50 mg group was 6%
100 days after SCT, 28% after 1 year, and 38% after 2 years
compared with 12% and 35% after 1 and 2 years, respectively,
after SCT within the 75 mg group. The cumulative NRM as
shown in Figure 3 and Table 3 was 46% after 2 years in the
50 mg group versus 27% after 2 years in the 75 mg Campath-
1H cohort. As speciﬁed in Table 2, causes for death were
mainly relapse and infectious complications. Applying
multivariate Cox regression analyses, pretransplantation
factors (as mentioned within the statistic section) were not
independently associated with relapse or NRM.
Survival
Probabilities of OS and DFS are plotted in Figures 4 and 5
and summarized in Table 3. The probability of OS in the
cohort receiving 50mg Campath-1Hwas 22% comparedwith
38% 2 years after SCT within the 75 mg group (P ¼ .38).
Median survival time was 13 months in the 50 mg Campath-
1H group and 12 months within the 75 mg Campath-1H
cohort. DFS after 2 years in the 50 mg group was 16%
versus 38% in the 75 mg group (P ¼ .38). Median time of DFS
was 11 months compared with 7 months within the 75 mg
Campath-1H group. Multivariate analysis revealed trans-
plantation from amatched sibling donor was associated with
signiﬁcantly better OS (hazard ratio, .40; 95% conﬁdence
interval; .16 to 1.0; P ¼ .05).
GVHD
The cumulative incidenceof acuteGVHD (grade I to IV)was
55% (18 patients) within 100 days after SCT (75 mg Campath-
1H cohort: 54%, 14 patients; P ¼ .87). Severe acute GVHD
(grades III and IV combined) occurred with a cumulative
incidence of 17% (5 patients) in the 50mg Campath-1H group
compared with 4% (1 patient) in the 75 mg group (P ¼ .15).
Chronic GVHD was observed in 44% (14 of 32) of patients
beyond day þ100. Eleven cases of extensive GVHD and 3
cases of limited GVHD were registered. After 1 year, the
incidence of chronic GVHD was 41% (13 of 32) (versus 27%, 7
of 26 in the 75 mg Campath-1H group after 1 year). The
incidence of extensive GVHD did not signiﬁcantly varyFigure 2. Cumulative incidence of relapse in the intention to treat population.
Study group (solid line) and control group (dashed line) in a competing risk
analyses to NRM.between both groups (P¼ .58). Inmultivariate Cox regression
analyses, no independent risk factor for acute or chronic
GVHD could be identiﬁed.
Therapy-Related Toxicity and Infections
Incidence and grading of extramedullary toxicities
occurring until day þ100 are summarized in the
Supplemental Material. Therewere no signiﬁcant differences
with regard to hepatic or renal toxicity as measured by the
maximum levels of total bilirubin, aspartate aminotrans-
ferase, and creatinine within the ﬁrst 100 days after
transplantation.
Seven cases (22%) of acute renal failure and 8 patients
(25%) suffering from hepatotoxicity (not otherwise speciﬁed)
were observed (P ¼ .31).
One hundred percent (23 of 23 CMV-positive recipients)
of the 50 mg Campath-1H group experienced CMV reac-
tivation as measured by positive PCR. Two patients (6%)
developed a visceral CMV disease (duodenitis and entero-
colitis) and 1 patient died because of CMV infection.
Eight patients (25%) showed an aspergillus antigen index
of >1.0 and 4 patients (13%) were scored “possible” by
radiological manifestations.
DISCUSSION
In contrast to our initial hypothesis, we did not observe
relevant reduction in the incidence of relapse after the doseFigure 3. Cumulative incidence of NRM in the intention to treat population.
Study group (solid line) and control group (dashed line) in a competing risk
analyses to relapse.
Figure 4. Kaplan-Meier plot for OS in the intention to treat population. Study group (solid line) and control group (dashed line).
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also true for NRM as well as for OS and DFS. Although the
Kaplan-Meier estimates suggest a different kinetics of dis-
ease relapse, this could not be formally proven because of the
limited number of patients. As expected, the less pronounced
in vivo T cell depletion led to a clinically nonsigniﬁcant trend
towards more acute GVHD grade III and IV. When comparingFigure 5. Kaplan-Meier plot for DFS in the intention to treat populathe cohort of patients receiving 50 mg Campath-1H with the
control group (75mg), it is important to note that themedian
age was signiﬁcantly higher in the latter (69 versus 65;
P ¼ .00) [19] and than previous cohorts receiving RIT in the
context of conditioning therapy [17,18]. The high incidence of
relapse, even in the cohort receiving 50 mg Campath-1H, can
in part be explained by the high-risk patient proﬁle withtion. Study group (solid line) and control group (dashed line).
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most cases, do not achieve durable remission before trans-
plantation, the consecutive disease burden and the risk of
relapse has to be regarded as being extremely elevated.
Second, graft-versus-leukemia effects are usually most
prominent in the early phase after SCT [30], when still rele-
vant plasma levels of Campath-1H can be assumed as its half-
life is 15 to 21 days [31]. Unfortunately, a reduction of
Campath-1H dosing was associated with an increase in the
incidence of severe acute GVHD, probably because of a less
pronounced suppression of T cells transplanted with the
graft. Thus, perhaps Campath-1H administration could be
carefully titrated towards earlier time points.
Furthermore, eradicating blasts by anti-CD66 radio-
immunotherapy can be questioned. The idea of cross-ﬁre
irradiation is based on the low numbers of blasts after in-
duction therapy and might, therefore, be less efﬁcient in
high-risk patients with an assumably higher leukemia
burden. Potentially, direct targeting strategies with radio-
immunoconjugates employing anti-CD33 or anti-CD45 an-
tibodies could be advantageous [32]. Anti-CD33mAbs, which
get internalized, linked with an a-emitter (213Be or 225Ac)
should in theory act more efﬁciently, especially [33,34].
In conclusion, lowering the dose of alemtuzumab did not
affect the incidence of relapse in this prospective phase II
trial. Potentially, antedating Campath administration could
be a strategy to test in the future. RIT can be safely applied
before SCT in elderly patients. Prospective randomized
comparisons of RIT combined with RIC and RIC alone as
comparator would be required to get more reliable insights.
Still, the current results suggest that a further optimization of
the current strategy has to be achieved before a head-to-
head comparison is likely to show a meaningful advantage
for RIT-based conditioning with or without in vivo T cell
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